ESMO 2022 | Combination therapies incorporating ADCs in breast cancer

Antibody-drug conjugates (ADCs) have recently made an impact on the treatment landscape of breast cancer, especially in HER+ breast cancer and more recently in ER+ and triple negative breast cancer (TNBC). Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, talks on enhancing the current treatment regiments by adding ADCs. Whilst immunotherapy and hormone therapies may be synergistic with ADCs, AKT and PARP inhibitors may not benefit from the addition of ADCs. The adoption of staggered dosing may additionally enhance the efficacy of ADCs in patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.